This site is intended for healthcare professionals
News

European Commission approval for Venclyxto + a hypomethylating agent for newly diagnosed acute myeloid leukemia . AbbVie

Read time: 1 mins
Last updated:26th May 2021
Published:26th May 2021
AbbVie announced that the European Commission (EC) has approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
Condition: Acute Myelogeous Leukemia (AML)
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest